<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table3" position="float"><object-id pub-id-type="doi">10.7554/eLife.46490.052</object-id><label>Table 3.</label><caption><title>Analysis of the cellular proteome for oxidised peptides encompassing reported sites of prolyl hydroxylation.</title><p>The number of unmodified and singly oxidised peptides containing reported sites of PHD-catalysed hydroxylation were counted over a range of stringency filters. Where multiple reported oxidation sites of one protein occur on separate peptides the number of spectra recorded is a summation of all interrogated peptides. The number of assigned target site prolyl oxidations is indicated in bold; methionine (Met) and alternate oxidation sites, including non-target proline residues (Other) are also presented together with unoxidised peptides for comparison. Stringency filters were applied as follows; PTM assignment confidence as assessed by ambiguity score (AScore:&gt;20) and fragment ion intensity (Ion Intensity:&gt;5%). These filters were applied separately and in combination to derive a list of assigned peptides with confidently localised oxidations. There are no high confidence proline oxidation assignments (i.e., meeting both AScore and Ion Intensity thresholds) of the reported substrates, suggesting a high degree of uncertainty from the software.</p><p><supplementary-material id="table3sdata1"><object-id pub-id-type="doi">10.7554/eLife.46490.053</object-id><label>Table 3&#8212;source data 1.</label><caption><title>Summary of non-enzymatic oxidation assignments on synthetic peptide standards.</title><p>MSMS assignment frequency of artefactual oxidations observed on unmodified tryptic peptide standards; oxidations are stratified by residue (e.g., Met, Pro, other). Reported assignments (column 4) were not subject to PTM localisation (AScore) filtering. Oxidations assigned to target Pro residues are indicated in red. Variation in the total number of peptide assignments (Column 5) reflects differences in the amount of peptide injected and/or replicate runs.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-46490-table3-data1-v1.docx"/></supplementary-material></p><p><supplementary-material id="table3sdata2"><object-id pub-id-type="doi">10.7554/eLife.46490.054</object-id><label>Table 3&#8212;source data 2.</label><caption><title>Peptide identification results from database search represented in <xref ref-type="table" rid="table3">Table 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46490-table3-data2-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th colspan="2" valign="bottom"><break/></th><th valign="bottom"/><th colspan="4" valign="bottom"># Spectra filtered by confidence of modification site</th></tr><tr><th>Gene ID</th><th colspan="2">Reported site</th><th>Assigned</th><th>No filter</th><th>AScore</th><th>Ion Intensity</th><th>AScore and Ion Intensity</th></tr></thead><tbody><tr><td>ACACB</td><td colspan="2">P343, P450, P2131</td><td>Unoxidised</td><td>63</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="4">ACTB</td><td colspan="2" rowspan="4">P307, P322</td><td><bold>P322</bold></td><td><bold>57</bold></td><td><bold>7</bold></td><td><bold>11</bold></td><td><bold>-</bold></td></tr><tr><td>Met</td><td>4528</td><td>647</td><td>4096</td><td>406</td></tr><tr><td>Other</td><td>336</td><td>58</td><td>62</td><td>7</td></tr><tr><td>Unoxidised</td><td>8650</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>ADRB2</td><td colspan="2">P382*, P395*</td><td>Unoxidised</td><td>1</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>AKT1</td><td colspan="2">P125, P313*, P318*, P423</td><td>Unoxidised</td><td>160</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>CENPN</td><td colspan="2">P311</td><td>Unoxidised</td><td>7</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="2">EEF2K</td><td colspan="2" rowspan="2">P98</td><td>Met</td><td>5</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Unoxidised</td><td>41</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="3">FLNA</td><td colspan="2" rowspan="3">P2317*, P2324*</td><td><bold>P2324</bold></td><td><bold>2</bold></td><td><bold>-</bold></td><td><bold>-</bold></td><td><bold>-</bold></td></tr><tr><td>Other</td><td>1</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Unoxidised</td><td>562</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>FOXO3</td><td colspan="2">P426*, P437*</td><td>Unoxidised</td><td>4</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="2">NDRG3</td><td colspan="2" rowspan="2">P294</td><td>Met</td><td>13</td><td>5</td><td>-</td><td>-</td></tr><tr><td>Unoxidised</td><td>49</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="3">PDE4D</td><td colspan="2" rowspan="3">P29, P382, P419</td><td>Met</td><td>14</td><td>13</td><td>9</td><td>9</td></tr><tr><td>Other</td><td>1</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Unoxidised</td><td>23</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="4">PKM</td><td colspan="2" rowspan="4">P403*, P408*</td><td><bold>P403</bold></td><td><bold>3</bold></td><td><bold>1</bold></td><td><bold>-</bold></td><td><bold>-</bold></td></tr><tr><td><bold>P408</bold></td><td><bold>5</bold></td><td><bold>-</bold></td><td><bold>-</bold></td><td><bold>-</bold></td></tr><tr><td>Other</td><td>5</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Unoxidised</td><td>3394</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="3">PPP2R2A</td><td colspan="2" rowspan="3">P319</td><td>Met</td><td>50</td><td>11</td><td>26</td><td>11</td></tr><tr><td>Other</td><td>18</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Unoxidised</td><td>119</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>SPRY2</td><td colspan="2">P18, P144, P160</td><td>Unoxidised</td><td>7</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>TELO2</td><td colspan="2">P374, P419, P422</td><td>Unoxidised</td><td>47</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>THRA</td><td colspan="2">P160*, P162*</td><td>Unoxidised</td><td>20</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>TP53</td><td colspan="2">P142, P359</td><td>Unoxidised</td><td>7</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td colspan="2" rowspan="5" valign="bottom"> <break/> <break/> <break/> <break/> <break/> <break/> <break/> <break/><break/></td><td rowspan="5"><bold>Total</bold></td><td>Pro</td><td>67</td><td>8</td><td>11</td><td>0</td></tr><tr><td valign="bottom">Met</td><td valign="bottom">4610</td><td valign="bottom">676</td><td valign="bottom">4131</td><td valign="bottom">426</td></tr><tr><td valign="bottom">Other</td><td valign="bottom">361</td><td valign="bottom">58</td><td valign="bottom">62</td><td valign="bottom">7</td></tr><tr><td valign="bottom">Unoxidised</td><td valign="bottom">13154</td><td valign="bottom">0</td><td valign="bottom">0</td><td valign="bottom">0</td></tr><tr><td valign="bottom">All</td><td valign="bottom">18192</td><td valign="bottom">742</td><td valign="bottom">4204</td><td valign="bottom">433</td></tr></tbody></table><table-wrap-foot><fn><p>*Doubly oxidised peptides were interrogated when multiple prolyl hydroxylation sites had been reported on the same tryptic peptide.</p></fn></table-wrap-foot></table-wrap>